Literature DB >> 22997172

Preliminary investigation of crosslinked chitosan sponges for tailorable drug delivery and infection control.

Ashley C Parker1, Jessica A Jennings, Joel D Bumgardner, Harry S Courtney, Ernö Lindner, Warren O Haggard.   

Abstract

Local versus systemic antibiotic delivery may be an effective strategy for treating musculoskeletal infections, especially when antibiotic-resistant bacteria are present. Lyophilized uncrosslinked, genipin crosslinked, and genipin crosslinked with poly(N-isopropylacrylamide) (PNIPAM) chitosan sponges were analyzed for their in vitro degradation rate, chemical crosslinking, antibiotic uptake, elution, biologic activity, and cytotoxicity. These evaluations were pursued to determine if crosslinking with genipin could be used to create a tailorable point of care loaded sponge for local infection control. Crosslinking the chitosan sponges decreased degradation in phosphate-buffered saline from 4.48 ± 2.28 wt % remaining of the uncrosslinked sponges to 78.82 ± 1.15 and 73.87 ± 1.27 wt % remaining at week 1 for the genipin and PNIPAM/genipin crosslinked sponges, respectively. The PNIPAM/genipin crosslinked sponges exhibited the most sustained release of biologically active antibiotics, with an average antibiotic release 63% higher than uncrosslinked and 37% higher than genipin crosslinked sponges, after 96 h. No significant cytotoxic effects from sponges or eluates were exhibited with NIH 3T3 fibroblasts. These preliminary results indicate that genipin crosslinked chitosan sponges, with or without PNIPAM, have potential as local delivery systems for adjunctive therapy for infection control, especially when longer degradation periods and higher antibiotic elutions are desired.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22997172     DOI: 10.1002/jbm.b.32822

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  7 in total

1.  Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis.

Authors:  Karen E Beenken; James K Smith; Robert A Skinner; Sandra G Mclaren; William Bellamy; M Johannes Gruenwald; Horace J Spencer; Jessica A Jennings; Warren O Haggard; Mark S Smeltzer
Journal:  J Biomater Appl       Date:  2014-05-21       Impact factor: 2.646

2.  Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm.

Authors:  Jessica Amber Jennings; Daniel P Carpenter; Karen S Troxel; Karen E Beenken; Mark S Smeltzer; Harry S Courtney; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2015-07       Impact factor: 4.176

3.  Blended Chitosan Paste for Infection Prevention: Preliminary and Preclinical Evaluations.

Authors:  Joel M Berretta; Jessica A Jennings; Harry S Courtney; Karen E Beenken; Mark S Smeltzer; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2017-07       Impact factor: 4.176

Review 4.  Control of Biofilm Formation: Antibiotics and Beyond.

Authors:  Ammar Algburi; Nicole Comito; Dimitri Kashtanov; Leon M T Dicks; Michael L Chikindas
Journal:  Appl Environ Microbiol       Date:  2017-01-17       Impact factor: 4.792

5.  Evaluation of a chitosan-polyethylene glycol paste as a local antibiotic delivery device.

Authors:  Cheyenne S Rhodes; Christopher M Alexander; Joel M Berretta; Harry S Courtney; Karen E Beenken; Mark S Smeltzer; Joel D Bumgardner; Warren O Haggard; J Amber Jennings
Journal:  World J Orthop       Date:  2017-02-18

6.  Development and Evaluation of an Injectable Chitosan/β-Glycerophosphate Paste as a Local Antibiotic Delivery System for Trauma Care.

Authors:  Logan Boles; Christopher Alexander; Leslie Pace; Warren Haggard; Joel Bumgardner; Jessica Jennings
Journal:  J Funct Biomater       Date:  2018-10-12

7.  Synthesis and Characterization of 2-Decenoic Acid Modified Chitosan for Infection Prevention and Tissue Engineering.

Authors:  Carlos Montez Wells; Emily Carol Coleman; Rabeta Yeasmin; Zoe Lynn Harrison; Mallesh Kurakula; Daniel L Baker; Joel David Bumgardner; Tomoko Fujiwara; Jessica Amber Jennings
Journal:  Mar Drugs       Date:  2021-09-29       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.